FutureMeds expand capacity, reach & capabilities.
Updated: Jan 24
FutureMeds are delighted to announce the acquisition of KCM, a leading clinical trial site based in Krakow, Poland. KCM was founded in 1994 and has successfully completed over 200 clinical trials. The site significantly increases our capacity and therapy area coverage and we look forward to working with Professor Czerwinski and his excellent team.
FutureMeds are also in advanced discussions with a number of other parties as we continue to build our site network across Europe to best serve our clients.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.